Summary: Establishment Labs has launched Preservé in Brazil, expanding its minimally invasive breast aesthetics platform with a focus on breast tissue preservation for more natural and stable results. Utilizing proprietary surgical tools and Ergonomix2 implants, Preservé aims to improve safety, recovery, and long-term outcomes, with a global rollout planned.

Key Takeaways:

  • Preservé builds on the technology of Mia Femtech to offer a less invasive alternative to traditional breast augmentation, enhancing safety, recovery, and aesthetic outcomes.
  • The new breast tissue preservation platform could expand the pool of women considering augmentation while driving growth and profitability for Establishment Labs.
  • After debuting in Brazil, Preservé will be introduced in other markets worldwide, though it is not yet approved for commercial use in the U.S.

Establishment Labs Holdings Inc, a global medical technology company focused on women’s health and wellness in breast aesthetics and reconstruction, announced it has launched Preservé in Brazil, the first country in its global rollout. Preservé is the second product in the company’s minimally invasive platform, building upon the technologies and techniques developed with Mia Femtech, Establishment Labs’ minimally invasive experience.

Addressing Patient Concerns with Minimally Invasive Solutions

“These are not small innovations, this is an entirely new era for aesthetic breast surgery,” said Juan José Chacón-Quirós, founder and CEO of Establishment Labs. “Whereas Mia made minimally invasive breast aesthetics possible for women looking for a one to two cup enhancement, Preservé allows less invasive breast surgery for the day-to-day breast augmentation patient.”

“Historically, many women have not been convinced by traditional methods and legacy techniques,” Chacón-Quirós continued. “With Mia and Preservé, we have solutions that address these concerns. The technology platform of breast tissue preservation allows plastic surgeons to create natural results with less disruption of the patient’s breast tissue. By improving safety profiles, recovery times, and achieving the breast aesthetic patients are looking for, breast augmentation may now be possible for women that otherwise never would have considered it—as well as making the decision easier for many who were already considering. After Brazil, Preservé will rollout globally over the next few years, and this should contribute to top line growth and profitability.”

Regulatory Status and U.S. Availability

The medical devices used in Preservé are not yet approved for commercial distribution in the United States.

Breast Augmentation with Tissue Preservation

According to the company, Preservé was designed to preserve breast tissue during aesthetic breast surgery, maintaining the structural anatomy and function of the breast for more stable and natural outcomes when compared to traditional breast augmentation. Preservé reportedly leverages Establishment Labs’ proprietary minimally invasive surgical tools coupled with the Ergonomix2 implants, which feature the patented SmoothSilk surface, designed for enhanced biocompatibility and softness; in addition, their shape adapts as the body changes position. Preservé is intended for primary augmentations up to four cups, hybrid augmentations, and mastopexy augmentations.

“Breast tissue preservation is a new paradigm in breast aesthetics. With less invasive breast procedures made possible by technology pioneered by Establishment Labs, we can address many of the complications that lead to reoperations,” said Dr Kamakshi Zeidler, San Francisco plastic surgeon and head of the Femtech board of Establishment Labs. “Preservé is an incredible new choice for women considering breast augmentation because it speaks to many of their aspirations, including smaller scars, quicker recovery, maintaining breast sensation, and avoiding unnecessary reoperations.”

Launch Event and Global Expansion Plans

The commercial launch of Preservé took place last weekend at the Brazilian Breast Meeting in Rio de Janeiro with over 300 surgeons in attendance and included live surgery and academic sessions. This year additional launches of Preservé are planned around the world.

Photo: ID 136326144 © Chernetskaya | Dreamstime.com